AU Patent

AU2024309346A1 — Particulate composition comprising ensifentrine

Assigned to Verona Pharma Ltd · Expires 2026-01-08 · 0y expired

What this patent protects

The invention relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt% to 0.60 wt% of 1,3-bis(2-(2-(mesitylimino)-9, 10-dimethoxy-4-oxo-6,7-dihydro-2H- pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl…

USPTO Abstract

The invention relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt% to 0.60 wt% of 1,3-bis(2-(2-(mesitylimino)-9, 10-dimethoxy-4-oxo-6,7-dihydro-2H- pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt% to 0.50 wt% of a biuret impurity of formula (A) relative to the total weight of ensifentrine. A liquid pharmaceutical composition comprising the particulate composition, and a process for producing the particulate composition are also described.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024309346A1
Jurisdiction
AU
Classification
—
Expires
2026-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Verona Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.